logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12570607 B1

PDFFull Text
Date of Patent:
Mar. 10, 2026

Filed:

Dec. 09, 2020

Compound as cyclin-dependent kinase 9 inhibitor and use thereof

Applicant:

Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, CN;

Inventors:

Zhenyu Wang, Shijiazhuang, CN;

Yan Zhang, Shijiazhuang, CN;

Yongzhao Mu, Shijiazhuang, CN;

Jianqiao Guo, Shijiazhuang, CN;

Hui An, Shijiazhuang, CN;

Na Gao, Shijiazhuang, CN;

Chaozai Zhang, Shijiazhuang, CN;

Jia Wang, Shijiazhuang, CN;

Assignee:

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, CN;

Attorney:

Buchanan Ingersoll & Rooney PC

Primary Examiner:

Andrew D Kosar

Assistant Examiner:

Phillip Matthew Rzeczycki

Int. Cl.
CPC ...
C07D 213/74 (2006.01); A61P 35/02 (2006.01); C07D 213/81 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 405/04 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01);
U.S. Cl.
CPC ...
C07D 213/74 (2013.01); A61P 35/02 (2018.01); C07D 213/81 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01);
Abstract

Disclosed is a compound as shown in formula (I) or a pharmaceutically acceptable salt, a stereoisomer, an isotope derivative or a prodrug thereof. The compound has an excellent activity as a cyclin-dependent kinase 9 (CDK9) inhibitor for treating hyperproliferative diseases. The experimental research on in vitro inhibition of cell proliferation and in vivo suppression of tumors shows that such compounds have a relatively strong inhibitory effect on MV4;11 cells and in vivo tumor models, and have a good selectivity and a low toxicity and few side effects, thereby possessing a good clinical value as novel anti-tumor drugs.

Find Patent Forward Citations

Wang, Zhenyu. (2026). Compound as cyclin-dependent kinase 9 inhibitor and use thereof (U.S. Patent No. 12570607). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12570607

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…